You can buy or sell SBBP and other stocks, options, and ETFs commission-free!
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide.
John H. Johnson
52 Week High
52 Week Low
Looking Into Strongbridge Biopharma's Return On Capital Employed
During Q1, Strongbridge Biopharma (NASDAQ:SBBP) brought in sales totaling $8.38 million. However, earnings decreased 3.15%, resulting in a loss of $10.07 millio
-$0.10 per share
-$0.11 per share